Latest Monoclonal antibodies Stories

Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech

2013-05-17 08:22:58

SAN JOSE, Calif., May 17, 2013 /PRNewswire-iReach/ -- Aridis is pleased to announce that an agreement has been reached with Switzerland-based Kenta Biotech to acquire Kenta's entire portfolio of anti-infective human monoclonal antibody (mAb) products, and technologies. This asset portfolio purchase includes six anti-infective human mAb products for treatment of infections by common pathogens including drug resistant bacterial strains of Staphylococcus aureus, Pseudomonas aeruginosa,...

AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease

2013-05-17 00:20:17

First selective JAK1 inhibitor to enter Phase 2 studies in Crohn's disease NORTH CHICAGO, Ill. and MECHELEN, Belgium, May 17, 2013 /PRNewswire/ -- Galapagos NV (Euronext: GLPG) and AbbVie (NYSE: ABBV) announced today an extension of their GLPG0634 clinical development collaboration to include Crohn's disease. Galapagos will fund and complete a Phase 2 program in Crohn's disease, which is designed to facilitate rapid progression into Phase 3. Upon successful completion of the...

Actinium Pharmaceuticals Clinical Results to be Presented at 8th International Symposium on Targeted Alpha Therapy Conference

2013-05-16 12:31:09

Actinium's lead drug candidate and technology platforms will be discussed in presentations at the TAT Symposium in Oak Ridge, TN June 4 - 6, 2013 NEW YORK, May 16, 2013 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (OTCBB: ATNM), a biopharmaceutical company that develops innovative targeted payload immunotherapeutics for treatment of advanced cancers, announced that the official program of TAT: Target Alpha Therapy (TAT) international symposium will feature a presentation devoted to...

RuiYi and Genor BioPharma Collaborate on Development in China of RYI-008, a Novel Therapeutic for Autoimmune Diseases and Cancer

2013-05-16 08:26:58

LA JOLLA, Calif. and SHANGHAI, May 16, 2013 /PRNewswire/ -- RuiYi Inc. announced today that it has entered into an exclusive license and collaborative development agreement with Genor BioPharma for the development of RYI-008 in China. RYI-008 is a novel anti-IL-6 monoclonal antibody with a unique pharmacologic profile that has the potential to define a new paradigm in the treatment of autoimmune diseases and cancer. "RYI-008, with its unprecedented femtamolar potency and amazing long...

Amgen Highlights Data To Be Presented At American Society of Clinical Oncology Annual Meeting

2013-05-15 20:22:49

THOUSAND OAKS, Calif., May 15, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will present data from several studies of both pipeline and marketed products at the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting from May 31 to June 4 in Chicago. "The data that we are presenting at ASCO demonstrate great progress with our effort to develop treatments that will help patients with advanced cancers," said Sean E. Harper, M.D., executive vice president...

SIMPONI® (golimumab) Receives FDA Approval for Ulcerative Colitis

2013-05-15 16:28:06

First and Only Subcutaneous Biologic Treatment Approved to Induce and Maintain Clinical Response and Improve Endoscopic Appearance of the Mucosa During Induction HORSHAM, Pa., May 15, 2013 /PRNewswire/ -- Janssen Biotech, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved SIMPONI(®) (golimumab) for the treatment of moderately to severely active ulcerative colitis (UC) in adult patients who have demonstrated corticosteroid dependence or who have had an...

Sanofi and Regeneron Announce Patient Enrollment in Two Phase 3 Trials with Sarilumab in Rheumatoid Arthritis (RA)

2013-05-15 00:21:05

Comprehensive SARIL-RA development program to include 2,600 patients in four Phase 3 and one open-label extension trials PARIS and TARRYTOWN, N.Y., May 15, 2013 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the COMPARE and ASCERTAIN trials of sarilumab, the first fully human monoclonal antibody directed against the IL-6 receptor, which is delivered by subcutaneous injection every other week, have enrolled...

CMC Biologics and RuiYi Enter into an Agreement for Development of a Novel Anti-IL-6 Monoclonal Antibody

2013-05-14 08:31:50

SEATTLE, COPENHAGEN, Denmark and SHANGHAI, May 14, 2013 /PRNewswire/ -- CMC Biologics today announced the execution of an agreement with RuiYi Inc. to develop a cell line for RYI-008, a novel anti-IL-6 monoclonal antibody. CMC Biologics' proprietary CHEF1® high-productivity expression plasmid will be utilized for the cell line development to optimize cell growth, and consistent, high-level protein expression in a rapid time frame. Specific terms of the agreement were not disclosed....

Perdue Kidd & Vickery Wins First Humira Trial - Abbott Laboratories To Pay $2.24 Million

2013-05-10 00:20:38

Jury ruled Abbott was Negligent in Alerting Doctors About the Increased Risks of Fungal Infections Associated with Humira CHICAGO, May 9, 2013 /PRNewswire/ -- Today, a Cook County jury entered a verdict finding Abbott Laboratories negligent and ordering it to pay $2,244,063.20 to Plaintiff Milton Tietz on behalf of his wife, Delores Tietz. The court entered judgment in that sum, plus costs, in favor of the Plaintiff. This is the first Humira lawsuit filed against Abbott to go to trial....

KaloBios to Present at Credit Suisse Antibody Conference

2013-05-08 16:27:37

SOUTH SAN FRANCISCO, Calif., May 8, 2013 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (NASDAQ:KBIO) today announced that the company will present at the Credit Suisse Antibody Conference, to be held in New York City on May 10, 2013. KaloBios President and Chief Executive Officer, David W. Pritchard, will provide an overview of KaloBios and the company's three current clinical programs for its proprietary, patient-targeted monoclonal antibody therapeutics. (Logo:...